Maraviroc

FDA Approved: * February 7, 2022
Pharm Company: * HETERO LABS UNIT III
Category: HIV / AIDS

Maraviroc, sold under the brand names Selzentry (US) and Celsentri (EU), is an antiretroviral drug in the CCR5 receptor antagonist class used in the treatment of HIV infection. It is also classed as an entry inhibitor. It also appeared to reduce graft-versus-host disease in patients treated with allogeneic bone marrow transplantation for leukemia, in a Phase I/II study.[5][6] Contents 1 Medical uses 2 Side effects 3 Mechanism of action 4 History 5 Names 6 See... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Maraviroc 150 mg Oral Tablet, Film Coated
NDC: 31722-579
Labeler:
Camber Pharmaceuticals, Inc.
Maraviroc 300 mg Oral Tablet, Film Coated
NDC: 31722-580
Labeler:
Camber Pharmaceuticals, Inc.
Maraviroc 300 mg Oral Tablet, Film Coated
NDC: 68475-007
Labeler:
Navinta LLC
Maraviroc 150 mg Oral Tablet, Film Coated
NDC: 68475-008
Labeler:
Navinta LLC
Maraviroc 150 mg Oral Tablet, Film Coated
NDC: 68554-3079
Labeler:
Hetero Labs Limited
Maraviroc 300 mg Oral Tablet, Film Coated
NDC: 68554-3080
Labeler:
Hetero Labs Limited
Maraviroc 150 mg Oral Tablet, Film Coated
NDC: 70710-1930
Labeler:
Zydus Pharmaceuticals USA Inc.
Maraviroc 300 mg Oral Tablet, Film Coated
NDC: 70710-1931
Labeler:
Zydus Pharmaceuticals USA Inc.
Maraviroc 150 mg Oral Tablet, Film Coated
NDC: 72319-024
Labeler:
I3 Pharmaceuticals, LLC
Maraviroc 300 mg Oral Tablet, Film Coated
NDC: 72319-025
Labeler:
I3 Pharmaceuticals, LLC
More Results

Related Brands

Drugs with the same active ingredients